While the FDA couldnt rule out a small risk, it noted that a study funded by the NIH found patients on semaglutide had a lower risk of suicidal thoughts compared to those on other diabetes and anti-obesity medications
The combination of low odds of success, limited near-term commercial potential even if the trial works, and the looming patent cliff suggests Novo's fundamental challenges extend well beyond the ZEUS outcome
[1] [3] The medication works by mimicking the incretin hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways
Sticking with a semaglutide diet and workout routines may manage weight after discontinuing the drug
All medications in the UK are tightly regulated, and Ozempic and Wegovy can only be purchased alongside a prescription